> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cancer Radiopharm. Dosage Guide
- URL: https://www.fdaweb.com/cancer-radiopharm-dosage-guide/
- Published: 2025-08-18T12:00:00.000Z
- Updated: 2026-09-14T15:19:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159699

FDA has released a new [draft guidance](https://www.fda.gov/media/188270/download?ref=fdaweb.com) entitled *Oncology Therapeutic Radiopharmaceuticals (RPTs): Dosage Optimization During Clinical Development*, highlighting the need for more tailored strategies to determine safe and effective dosages.

RPTs are drugs that deliver radiation systemically to treat cancer and share properties of both external beam radiation therapy (EBRT) and systemic drug therapy. Traditionally, FDA says their dosing has been based on EBRT-derived organ tolerance limits. However, it notes that differences in how RPTs distribute and deliver radiation make those limits less reliable for guiding development.

The guidance emphasizes that RPTs can cause long-term or delayed toxicities — such as kidney damage, bone marrow failure, or glandular dysfunction — that may not appear during the short “dose-limiting toxicity” window typically used in early clinical trials. As a result, the agency is urging sponsors to adopt trial designs that account for cumulative exposure risks and ensure adequate long-term follow-up before moving to larger studies.

“Limiting cumulative exposure is a well-established practice in cancer treatment,” the document says, pointing to radiation therapy, platinum chemotherapy, and anthracyclines as examples where long-term toxicities dictate treatment duration. The agency advises that RPT trials should similarly balance evidence generation with safeguards to prevent overdosing.

Key recommendations include:

- Trials testing doses that exceed EBRT-derived limits should be conducted in patients with advanced cancers and limited life expectancy, where the risks of delayed organ damage may be more acceptable.
- Patients with earlier-stage cancers or longer expected survival should only be treated with doses already characterized in higher-risk populations.
- Prior treatment with EBRT or other RPTs should not automatically exclude patients, but trial eligibility should be based on clinical factors such as organ function and cumulative absorbed radiation doses.
- Sponsors are encouraged to define maximum cumulative doses to critical organs and justify any proposals to exceed them.

The draft guidance builds on FDA’s 2024 framework for optimizing oncology drug doses, which moved away from the historic reliance on maximum tolerated dose (MTD) and emphasized tailoring treatment to balance efficacy with toxicity.

Comments are being accepted on the guidance until 10/20.